Apologies, I found the full year 2023 stuff which has not been posted here in HC, other stuff is missing too, which is strange:
In 2022 EYE had revenues (sales/gross income) of $13.378 mil and a net loss of $7.817 - expenses of $21.195 mil.
In 2023 EYE had revenue of $17 mil and a loss of $17 mil, so expenses of $34 mil, of which there was $6.044 mil recorded as a one off impairment, obviously with normalised expenses of $28 mil.
In 2024 income has been $23.5 mil, so it remains to be seen how much expenses have risen. They are expected to have risen substantially and there will be a significant loss.
*The impairment item was due to the inability of the AlphaRET segment to generate independent cashflows, requiring a cash investment of $6.044 mil, more than the company has available. Not quite a one off non cash item as characterised by TheAnalyst007
- Forums
- ASX - By Stock
- EYE
- EYE Summary (August 2024): Incredibly Undervalued
EYE
nova eye medical limited
Add to My Watchlist
8.00%
!
13.5¢

EYE Summary (August 2024): Incredibly Undervalued, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
13.5¢ |
Change
0.010(8.00%) |
Mkt cap ! $38.35M |
Open | High | Low | Value | Volume |
13.5¢ | 14.5¢ | 13.0¢ | $271.5K | 1.986M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 206547 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.5¢ | 2538 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 206547 | 0.130 |
8 | 130901 | 0.125 |
10 | 710607 | 0.120 |
2 | 301331 | 0.115 |
6 | 656828 | 0.110 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 2538 | 2 |
0.140 | 278401 | 7 |
0.145 | 566939 | 5 |
0.150 | 319348 | 7 |
0.160 | 145480 | 3 |
Last trade - 12.34pm 08/07/2025 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |